Dr. Mark Thornton

---

Dr. Mark O. Thornton serves as a Clinical Advisor to Cartago Biotech, providing strategic guidance on clinical development, regulatory strategy, and risk assessment as the company advances its therapeutic programs.

Dr. Thornton brings more than 20 years of experience across government, industry, and consulting. His career includes six years at the U.S. Food and Drug Administration (FDA) Center for Biologics Evaluation and Research (CBER) and 14 years in senior leadership roles within biotechnology and pharmaceutical companies. Most recently, he served as Chief Medical Officer and Chief Development Officer at companies developing innovative therapies, primarily in oncology, and has contributed to programs resulting in the FDA approval of two Biologics License Applications.

In addition to his advisory role at Cartago, Dr. Thornton advises investment and venture capital firms on clinical, safety, and regulatory due diligence. He is widely recognized for his expertise in FDA regulatory policy and has authored five op-eds in The Wall Street Journal on drug development policy.